News Focus
News Focus
icon url

dennisdave

07/06/25 2:21 PM

#774411 RE: exwannabe #774408

100% agree Powerless is a fraud and a criminal and is responsible for the suffering of cancer patients that could otherwise have been treated otherwise had she run nwbo as a proper biotech.
icon url

skitahoe

07/06/25 2:37 PM

#774413 RE: exwannabe #774408

EX, you know as well as anyone here that you cannot apply if you don't have a commercial production facility ready for inspection in a timely manner.

Clearly the EDEN is NWBO's choice for commercial production. I'm uncertain if the EDEN was permitted for compassionate use, if it was the record there ought to be sufficient. Again, an EUA for the EDEN would be an answer permitting its use could be an answer.

Time and cost never seem to matter to the regulators, they're going to do things there way and if it takes many years and costs hundreds of millions more, they don't seem to care, nor do they care about all who won't get the benefits.

All this could also be prevented if the right to try program was changed so that all developers would participate. Few do because to do so corporate proprietary information must be divulged and few are willing to do so. As long as right to try would also cover the use of the EDEN, it should work here the way the compassionate use program is working in the UK.

On the other hand, if you said you can try it under right to try, but it must be made manually, you'd have the same production problem that is the case today.

Gary
Bullish
Bullish
icon url

Investor082

07/06/25 2:48 PM

#774416 RE: exwannabe #774408

Agreed. There will ways be excuses and victim mindset. No reimbursement evidence submission in the UK. No European regulatory submission. No Canadian or US submission either. No one has been stopping them from any of this. That too, 5 years since data lock and it’s always someone else’s fault.

This group will never succeed and be able to deliver ROI to shareholders. No wonder, all savvy and credible institutional investors and big pharma run as far away from NWBO as possible despite LP bending over backwards for years. They are a bunch of inept and lying crew that has done nothing but lost investor money over the last 15 years. It’s a dilution scam!
icon url

SkyLimit2022

07/06/25 2:59 PM

#774419 RE: exwannabe #774408

e❌wannabe,

Thanks for continuing to share your free advice and x-ceptional x-pertise 😶

Multiple novel patent-fortified dendritic cell technology platforms that are in-licensed to NWBO are in clinical trials TODAY and patients are being treated TODAY. The fact that NWBO does not need to sponsor or fund those trials is a major win for several reasons:

✅️ No cost (or very minimal cost) to the company
✅️ Independent scientific validation by peer-reviewed grants
✅️ U.S. government agency investment/buy-in



Fact ✅️: Merck is one of the supporting collaborators for the UCLA combo with pembrolizumab.

Combos with commercialized agents such as checkpoint inhibitors represent a relatively recent development—those studies have reached PII as of 2025. Undoubtedly, more combo trials are coming, potentially funded by NWBO and/or industry partner(s). However, it is misleading to suggest that there are “no active trials” today involving the DC technology platforms owned by the company. NWBO’s platforms have been under continuous clinical development for many years, and we have now entered an exciting new stage of COMBO research. Another super exciting development is the recent addition of technology created by Roswell Park!

⭐️ DCVax-L Combo PII UCLA

⭐️ DC Combo PII Roswell Park

NWBO 10-Q

NICE UK 🇬🇧 DCVax-L

ASM June 29, 2024

Manufacturing Technology























AI Fact-Checking
Bullish
Bullish
icon url

RobotDroid

07/06/25 3:30 PM

#774424 RE: exwannabe #774408

Linda pos got rich and thats all she cares about.